Julia Johansen

Professor

Copenhagen University Hospital

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Julia Johansen is a Professor at Herlev and Gentofte Hospital, University of Copenhagen, Denmark. Her research primarily focuses on pancreatic cancer, including the prognostic impact of ctDNA kinetics, therapeutic monitoring through cell-free DNA analyses, and the evaluation of biomarkers in cancer prognosis. She has contributed to significant studies on the efficacy of immunotherapy and radiation in combination with novel cancer treatments, as well as investigations into the role of inflammatory markers in cancer outcomes.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (18)

Astrid Zedlitz Johansen

department of oncology copenhagen university hospital–herlev and gentofte herlev denmark

DENMARK

Julia Johansen

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

The prognostic impact of early ctDNA kinetics in metastatic pancreatic cancer using the ctDNA Response Evaluation Criteria in Solid Tumors (ctDNA-RECIST)

A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)

Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer

Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study

Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer

Combined plasma C‐reactive protein, interleukin 6 and YKL‐40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer

Preoperative plasma vitamin D in patients with localized colorectal cancer: Age-dependent association with inflammation, postoperative complications, and survival

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer

Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification

Collaborators (18)

Astrid Zedlitz Johansen

Heikki Joensuu

Benny V. Jensen

Ole Thorlacius-Ussing

Estrid V. Hoegdall

Colm O'Rourke

Morten Ladekarl

Harri Kalevi Mustonen

Inge Søkilde Pedersen

Caroline Kistorp

Henrik Krarup

Sidsel Christy Lindgaard

Pirkko-Liisa Kellokumpu-Lehtinen

Jacob Bjerrum

Ole Haagen Nielsen

Pia Osterlund

Kirstine Kloeve-Mogensen

Benjamin Emil Stubbe

Make your next move.